Integrated Diagnostics Holdings PLC
IDHC.L operates in the healthcare facilities and services industry, providing biotechnology-related services and equipment, and generates revenue primarily through its operations in this sector.
Business. IDHC.L is a healthcare company operating within the Healthcare Facilities & Services industry, with activities focused on biotechnology. The firm is listed on the London Stock Exchange under the ticker IDHC.L. Specific details regarding its operating segments, headquarters location, and geographic presence are not available in the provided data. Consequently, the company is described at the industry level as a provider of healthcare services and facilities.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
IDHC.L is a healthcare company operating within the Healthcare Facilities & Services industry, with activities focused on biotechnology. The firm is listed on the London Stock Exchange under the ticker IDHC.L. Specific details regarding its operating segments, headquarters location, and geographic presence are not available in the provided data. Consequently, the company is described at the industry level as a provider of healthcare services and facilities.
IDHC.L maintains a relatively strong liquidity position, with a current ratio of 1.46, indicating the company can cover its short-term liabilities with its short-term assets. However, the company's liquidity risk is assessed as medium, and it is worth noting that net cash is negative after subtracting total debt, suggesting potential pressure on its cash reserves.
In terms of profitability, IDHC.L demonstrates a return on equity (ROE) of 37.31% and a return on assets (ROA) of 14.69%, both of which are strong indicators of efficient use of equity and assets to generate profit. The company's operating income of 2.17 billion EGP and net income of 1.26 billion EGP further support its profitability.
The company's revenue is concentrated within the biotechnology segment, with no disclosed geographic diversification in the provided data. This concentration may expose the company to specific market risks, particularly in the biotechnology sector.
Looking at the growth trajectory, IDHC.L has shown a strong performance in recent periods, with a gross profit of 3.35 billion EGP and a free cash flow of 470.61 million EGP. However, the outlook for the next fiscal year is not explicitly provided in the data, and the company's capital expenditure of -861.04 million EGP suggests a reduction in investment in physical assets.
The risk assessment for IDHC.L indicates a low potential for dilution, with no significant dilution sources identified in the provided data. The company's debt-to-equity ratio of 0.48 suggests a moderate level of leverage, and the risk of dilution is considered low.
Recent events and filings do not provide specific details on new developments or strategic changes for IDHC.L. The company's financial performance and risk profile remain stable, with no major disruptions reported in the latest data.
- IDHC.L has a strong return on equity (37.31%) and return on assets (14.69%), indicating efficient use of capital.
- The company's liquidity position is moderate, with a current ratio of 1.46, but net cash is negative after subtracting total debt.
- IDHC.L's revenue is concentrated in the biotechnology segment, which may expose it to sector-specific risks.
- The company's capital expenditure is negative, suggesting a reduction in investment in physical assets.
- The risk of dilution is low, and the company's debt-to-equity ratio is moderate at 0.48.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 2,89 |
| Revenue | —no estimate | —no estimate | 9,2B EGP |
| Operating income | —no estimate | —no estimate | 2,6B EGP |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- IDHC.L Market data — financials · 2026-05-28
- Integrated Diagnostics Holdings PLC Market data — analyst estimates · 2026-05-28